Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Recommendation of "Hold" from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has received an average rating of "Hold" from the five research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.6667.

LXRX has been the subject of a number of research reports. Wall Street Zen assumed coverage on Lexicon Pharmaceuticals in a report on Monday, April 21st. They issued a "sell" rating for the company. HC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday, June 24th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP increased its stake in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 15,249 shares in the last quarter. Cerity Partners LLC grew its stake in Lexicon Pharmaceuticals by 328.7% in the 4th quarter. Cerity Partners LLC now owns 96,512 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 74,000 shares during the period. Invesco Ltd. increased its holdings in Lexicon Pharmaceuticals by 60.6% in the 4th quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 39,420 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Lexicon Pharmaceuticals during the fourth quarter worth $38,000. Finally, Barclays PLC lifted its holdings in Lexicon Pharmaceuticals by 25.5% during the fourth quarter. Barclays PLC now owns 243,316 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 49,443 shares in the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Trading Down 2.2%

NASDAQ LXRX traded down $0.03 on Monday, hitting $1.13. 2,374,852 shares of the stock were exchanged, compared to its average volume of 9,013,905. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.18. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.22. The stock has a fifty day moving average price of $0.93 and a two-hundred day moving average price of $0.71. The firm has a market capitalization of $406.68 million, a P/E ratio of -2.19 and a beta of 1.17.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. The company had revenue of $1.26 million during the quarter, compared to analysts' expectations of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. Research analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.